| Fiscal Year End | Company Status | Exempt Flag |
| July 31 | Suspend | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 29/Aug/1988 | | Canada | | |
|
|
| Exchange Filing Office |
| Location |
| NEX Service Office |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| Scientific Research And Development Services
| About APC (From News Release July 31, 2013)
APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has an affinity for cancer cells.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| APC.H | Advanced Proteome Therapeutics Corporation | TSX Venture | SUSPEND |
|
|
| Name History | From | To |
| Advanced Proteome Therapeutics Corporation | 3/Nov/2006 | Present |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
